Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Saved in:
| Title: | Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. |
|---|---|
| Authors: | Sheik Ali S; King's College London School of Medicine, London, England., Goddard AL; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Center for Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Luke JJ; Melanoma Disease Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Donahue H; Melanoma Disease Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Todd DJ; Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Werchniak A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Center for Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Vleugels RA; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. |
| Source: | JAMA dermatology [JAMA Dermatol] 2015 Feb; Vol. 151 (2), pp. 195-9. |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
